Bioventix has completed a US$1.4 million sell-down of founder’s equity
Bioventix Plc has raised funds through a sell-down of the founder’s equity.
Bioventix was founded in 2003 as a biotechnology company specializing in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics such as clinical blood testing.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker in respect of the sell-down of the founder’s equity.
Talk to the deal team
Related deals
Winking Studios Limited completes a secondary fundraising of US$20 million
Winking Studios has successfully raised US$20 million to fund its business strategy and future plans, such as strategic acquisitions, alliances and joint ventures as well as secondary or dual listings, to grow the group’s market share and broaden its customer base globally.
Learn moreFRP Advisory Group plc has finalized a successful secondary placing
FRP Advisory Group plc has completed a fundraising. The book was oversubscribed and approximately £20.4 million (US$33 million) of shares were sold by certain directors and partners of FRP to new and existing institutional investors at 128 pence per ordinary share.
Learn moreLeika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Learn more